Tadalafil
Also known as: Cialis, Adcirca
Classification
Pharmaceutical
Regulatory Status
FDA-approved prescription product
Sources
1
Review
n/a
Overview
Tadalafil inhibits phosphodiesterase type 5 (PDE5), increasing cyclic GMP in smooth muscle and promoting vasodilation in the corpus cavernosum and pulmonary vasculature.
Evidence and limitations
Human/preclinical evidence breakdown is not available in this record.
Pathways
Benefits
Studied and labeled for erectile dysfunction and BPH (Cialis) and pulmonary arterial hypertension (Adcirca); BioStack presents labeled use context only, not a personal recommendation.
Interactions & cautions
Flagged in source data
Drug interactions
organic nitrates — Potentially life-threatening hypotension (high)
alpha-blockers — Symptomatic hypotension may occur (review)
strong CYP3A4 inhibitors — Increased tadalafil exposure and adverse-effect risk (review)
These are observational flags for review, not individualized instructions.
Sources
Educational reference only — not medical advice.
What people report (anecdote)
CLINICAL DATA (from trials)
Adverse events:
None recorded in our sources.
Effects measured:
Human trials: none found.
ANECDOTE
What people report: anecdote, not evidence
Loading…
Submit a claim you saw